It was Patisiran (Onpattro®), developed by Alnylam Pharmaceuticals as an siRNA–LNP complex designed to reduce transthyretin protein formation and to treat hereditary transthyretin-mediated amyloidosis, representing a milestone in nucleic acid therapeutics [54]. The gene discussed is TTR; the disease is amyloidosis.